KLOW blend
A mix of four separate compounds sold together in one vial: BPC-157, TB-500, GHK-Cu and KPV. None of the four is approved as a medicine. There are no published studies of this combination, in people or in animals.
Approval status
None of the four parts is approved as a medicine in any country. FDA’s compounding reviews cover each part on its own, not this mix. See each part for its status.123
What it’s used or studied for
There are no published studies of this combination itself. See the page for each part.
Each label shows how strong the evidence is: an approved use, human studies, animal or lab studies only, or a popular claim with no published studies. Being studied is not the same as being proven safe or effective.
Side effects
There are no studies of this combination.
A blend carries the side effects and cautions of each of its parts.
Sources
- FDA: Bulk drug substances used in compounding that may present significant safety risks (current as of April 2026)
- FDA: Bulk drug substances nominated for compounding under section 503A, categories 1 to 3 (updated May 14, 2026)
- World Anti-Doping Agency: 2026 Prohibited List (in force from January 1, 2026)
Spotted a mistake on this page? Report it. The email opens with the peptide and vial already filled in.